WELLS FARGO & CO

Wells Fargo’s January 2026 trading shows modest net purchases amid large sell‑orders, while its research updates raise targets for tech, industrial and consumer stocks—highlighting disciplined, value‑focused upside potential.

Wells Fargo’s recent institutional trades show active buying by top wealth managers and a balanced liquidity profile amid renewed media buzz.

Wells Fargo’s new research push raises targets for Take‑Two, eBay and biotech, while trimming Guidewire, CoreWeave and D.R. Horton—how will this shift impact its own stock and investors?

Wells Fargo’s 2026 headcount cut, crypto‑policy lobbying, and volatile analyst ratings highlight a strategic pivot that could reshape risk and earnings.

Wells Fargo adjusts valuations: trims REIT targets, boosts outlook for Merck & Agilent, showing a balanced strategy for investors.

Wells Fargo & Co. balances a diversified banking model with rising regulatory scrutiny—investors weigh stable earnings, risk‑management focus, and strategic pivots to gauge its next‑phase value.

Wells Fargo’s record 86,319 call‑option spike signals growing bullish confidence, while its expanded research pushes upside on key non‑bank stocks, shaping investor outlook.

Wells Fargo & Co. has reported a 9% year-over-year increase in net income to $5.589 billion, exceeding expectations and solidifying its position as a resilient player in the US banking sector.

Wells Fargo & Co. reported a strong second-quarter earnings performance, exceeding expectations, but faced challenges in net interest income due to economic pressures.

Wells Fargo & Co. remains a focal point for investors and analysts, with strong analyst support and a solid market position, despite recent analyst downgrades and market fluctuations.